Abdullah KARAER, Senem ARDA DÜZ, Görkem TUNCAY

Clinical and hormonal characteristics of women with various phenotypes of polycystic ovary syndrome

Aim: The goal of this study is to identify clinical and hormonal characteristics of women with various phenotypes of polycystic ovarysyndrome.Material and Methods: One hundred seventy eight cases, between the ages 18-30, diagnosed with PCOS, up to Rotterdam criteria, inour clinic between February 2015 -November 2018 were recruited in this cross sectional study.Results: The number was declined 89 by using National Institutes of Health criteria, 132 up to Androgen Excess and PCOS Societycriteria. 34.83% of the patients were phenotype A, 15.16% were phenotype B, 24.15% were phenotype C and 25.84% were phenotypeD. When we compared the different phenotypes with each other, body mass index, fasting glucose, postprandial glucose, fastinginsulin and homeostatic model assessment for insulin resistance were found to be higher in phenotype A. In addition, luteinizinghormone and luteinizing hormone to follicle stimulating hormone ratio was higher in phenotype D than in B and C. When multivariateanalysis was performed, body mass index was found to be as a single statistically significant predictive factor on IR.Conclusion: Body mass index was the most effective factor on insulin resistance and the mean body mass index was significantlyhigher in phenotype A.

PDF

___

1. Speroff L, Fritz MA. Clinical Gynecologic Endocrinology and Infertility, 7th edn. Philadelphia: Lippincott Williams & Wilkins 2005.
2. Norman RJ, Masters L, Milner CR, et al. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001;16:1995-8.
3. Wild S, Pierpoint T, McKeigue P, et al. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000;52:595-600.
4. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia inwomen with polycystic ovary syndrome. Am J Med 2001;111:607-13.
5. Jedel E, Waern M, Gustafson D, et al. Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. Hum Reprod 2010;25:450-6.
6. Boomsma CM, Eijkemans MJ, Hughes EG, et al. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006;12:673-83.
7. Chang WY, Knochenhauer ES, Bartolucci AA, et al. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril 2005;83:1717- 23.
8. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Dunaif A, Givens JR, Haseltine FP, Merriam GR (eds). Polycystic Ovary Syndrome. Boston: Blackwell Scientific 1992;377-84.
9. Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237-45.
10. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7.
11. National Institutes of Health. Evidence-based methodology workshop on polycystic ovary syndrome, December 3-5, 2012. Executive summary. Available at: https://prevention.nih.gov/docs/programs/pcos/ FinalReport.pdf. Accessed March 1, 2016
12. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-91.
13. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-7.
14. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-95.
15. Yilmaz M, Isaoglu U, Delibas IB, et al. Anthropometric, clinical and laboratory comparison of four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. J Obstet Gynecol Research 2011;37:1020-6.
16. Kar S. Anthropometric, clinical, and metabolic comparisons of the four Rotterdam PCOS phenotypes: a prospective study of PCOS women. J Hum Reprod Sci 2013;6:194-200.
17. Kavardzhikova S, Pechlivanov B. Clinical, hormonal and metabolic characteristics of different phenotypes of polycystic ovary syndrome, Bulgarian population. Akush Ginekol (Sofiia) 2010;49:32-7.
18. Mehrabian F, Khani B, Kelishadi R, et al. The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative sample of Iranian females. J Res Med Sci 2011;16:763-9.
19. Zhang HY, Guo CX, Zhu FF, et al. Clinical characteristics, metabolic features, and phenotype of Chinese women with polycystic ovary syndrome: a large-scale casecontrol study. Arch Gynecol Obstet 2013;287:525-31.
20. Yildiz BO, Bozdag G, Yapici Z, et al.Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. HumReprod 2012;27:3067-73.
21. Pehlivanov B, Orbetzova M. Characteristics of different phenotypes of polycystic ovary syndrome in a Bulgarian population.Gynecol Endocrinol 2007;23:604-9.
22. Carmina E, Chu MC, Longo RA, et al. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 2005; 90:2545-9.
23. Jamil AS, Alalaf SK, Al-Tawil NG, et al. Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria. Arch Gynecol Obstet 2016;293: 447–56.
24. Cupisti S, Haeberle L, Schell C, et al. The different phenotypes of polycystic ovary syndrome: no advantages for identifying women with aggravated insulin resistance or impaired lipids. Exp Clin Endocrinol Diabetes 2011;119:502-8.
25. Panidis D, Tziomalos K, Misichronis G, et al. Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum Reprod 2012;27:541-9.
26. Dewailly D, Catteau-Jonard S, Reyss AC, et al. Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. J Clin Endocrinol Metab 2006;91:3922-7.
27. Clark NM, Podolski AJ, Brooks ED, et al. Prevalence of Polycystic Ovary Syndrome Phenotypes Using Updated Criteria for Polycystic Ovarian Morphology: An Assessment of Over 100 Consecutive Women Selfreporting Features of Polycystic Ovary Syndrome. Reprod Sci 2014;21:1034-43.
28. Barber TM, Wass JA, McCarthy MI, et al. Metabolic characteristics of women with polycystic ovaries and oligoamenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007;66:513-7.
29. Diamanti-Kandarakis E, Panidis D. Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clin Endocrinol (Oxf) 2007;67:735-42.